TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients
Clinical trial NCT07489755 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07489755
- Sponsor
- Shenzhen TargetRx Co., Ltd.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-04-01
- Primary completion
- 2030-05-01
- Enrollment
- 180
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.